• GW Pharmaceuticals PLC (GWPH) Dips More Than Broader Markets: What You Should Know
    Zacks

    GW Pharmaceuticals PLC (GWPH) Dips More Than Broader Markets: What You Should Know

    GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $118.11, moving -0.85% from the previous trading session.

  • E-Cigarette Ban in New York: Impact on Cannabis Sector
    Market Realist

    E-Cigarette Ban in New York: Impact on Cannabis Sector

    The vaping crisis has brought on some twists and turns for the cannabis sector. New York courts are now weighing an e-cigarette ban.

  • AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review
    Zacks

    AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review

    AstraZeneca (AZN) announces acceptance of BLA seeking approval for trastuzumab deruxtecan in metastatic breast cancer by the FDA. The FDA also grants priority review.

  • Pot stocks ‘significantly oversold’: ETF manager
    Yahoo Finance

    Pot stocks ‘significantly oversold’: ETF manager

    Legal pot could provide "significant upside" for investors, ETF manager says

  • 3 Medical Product Stocks Likely to Beat This Earnings Season
    Zacks

    3 Medical Product Stocks Likely to Beat This Earnings Season

    Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

  • Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow
    Zacks

    Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow

    FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3

  • IHG, SmileDirectClub, Wells Fargo, AT&T and AB InBev: Stocks to Watch
    Yahoo Finance

    IHG, SmileDirectClub, Wells Fargo, AT&T and AB InBev: Stocks to Watch

    IHG, SmileDirectClub, Wells Fargo, AT&T and AB InBev are the stocks to watch

  • Can Monster Beverage's Growth Strategies Aid a Turnaround?
    Zacks

    Can Monster Beverage's Growth Strategies Aid a Turnaround?

    Monster Beverage (MNST) is facing headwinds related to higher freight costs and adverse currency. Nevertheless, its constant product launches and innovations may provide some respite.

  • Market Realist

    Why Did HEXO Rise 17% on Thursday?

    Hexo (HEXO) had a hard time last week. A lot of headwinds pulled the stock down. However, the stock rose and closed with a gain of 17% on Thursday.

  • Cannabis 2.0: What Products Can Canadians Expect?
    Market Realist

    Cannabis 2.0: What Products Can Canadians Expect?

    The Cannabis 2.0 era has officially started. Now, Canadians can legally access a host of cannabis-infused products like beverages, vapes, and edibles.

  • Aurora Cannabis Plans to Launch Vapes despite Concerns
    Market Realist

    Aurora Cannabis Plans to Launch Vapes despite Concerns

    Despite vaping concerns, Aurora Cannabis plans to introduce vape products in December. Reports of vaping-related illnesses started in late August.

  • Juul Suspends Sale of Most E-Cigarette Flavors in U.S.
    Bloomberg

    Juul Suspends Sale of Most E-Cigarette Flavors in U.S.

    (Bloomberg) -- Juul Labs Inc., the largest e-cigarette maker in the U.S., is suspending sales of most nicotine pod flavors nationwide, bending to pressure from officials and the public who said sugary flavors were hooking teens.Fruit and dessert flavors, which the company was selling to people over 21 through its website, are no longer available in the U.S. pending a review by the Food and Drug Administration, Juul said. It will continue selling mint, menthol and tobacco flavor pods in stores and online.The creators of Juul have said they designed e-cigarettes to help longtime smokers switch, but the popular devices have also introduced a generation of teens and young adults to nicotine. Scott Gottlieb, the former FDA commissioner who declared youth vaping an epidemic, said Juul’s decision to continue selling mint and menthol won’t solve the problem. “Mint is a candy flavor,” Gottlieb said. “A lot of the youth use has shifted to that flavor.”Juul said the new sales restriction comes out of a review led by the new chief executive officer, K.C. Crosthwaite, who joined last month from tobacco giant Altria Group Inc. As part of that review, Juul said last month it would stop all U.S. advertising, refrain from supporting a proposition to voters in San Francisco that would reverse an e-cigarette ban and stop lobbying the government about legislation related to flavors. Michael Bloomberg, the founder and majority owner of Bloomberg LP, funds anti-vaping advocacy initiatives, including one to defeat the San Francisco ballot measure.Shares of Altria, which sells Marlboro in the U.S. and is Juul’s largest shareholder, were up 1.2% to $44.05 at 2 p.m. in New York. “We must reset the vapor category by earning the trust of society and working cooperatively with regulators, policymakers, and stakeholders to combat underage use while providing an alternative to adult smokers,” Crosthwaite said in a statement.The new policy began Thursday and affects sales on its website of the flavors fruit, creme, mango and cucumber. Online purchases of the remaining flavors will continue to be screened by Juul’s age verification system.Juul had stopped the distribution of those flavors last November to physical retailers in the U.S., a move it made in anticipation of sales restrictions from the FDA on flavored e-cigarette products. That move led to a slight dip in sales, but the San Francisco-based company has largely recovered, thanks partly to international growth.In the U.S., Juul controls 70% of vape sales, according to market research firm IRI, which doesn’t track online sales. Investors valued Juul at $38 billion in December, before growing outrage in recent months led to the departure of its previous CEO.In September, Health and Human Services Secretary Alex Azar said that U.S. health monitors had seen a continuing rise in youth use, including of flavors like mint and menthol. He said the Trump administration’s goal was to ban those flavors and leave only tobacco-flavored e-cigarettes on the market.Juul is still evaluating which products and flavors to submit for regulatory approval in May, which means some of these flavors could return to shelves if the FDA approves them. Josh Raffel, a spokesman for Juul, said the company could also extend its temporary sales ban to other flavors, such as mint and menthol. “We continue to review our policies and practices in advance of FDA’s flavor guidance and have not made any final decisions,” he said.(Updates with market share data in the eighth paragraph.)To contact the authors of this story: Ellen Huet in San Francisco at ehuet4@bloomberg.netDrew Armstrong in New York at darmstrong17@bloomberg.netTo contact the editor responsible for this story: Mark Milian at mmilian@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Why Cronos Rose 33% in After-Hours Trading on Wednesday
    Market Realist

    Why Cronos Rose 33% in After-Hours Trading on Wednesday

    Cronos Group (CRON) stock rose 33% with a heavy volume in after-hours trading on Wednesday. Marijuana stocks are on a rollercoaster ride.

  • Cresco Labs Stock Rises on Dispensary Approval
    Market Realist

    Cresco Labs Stock Rises on Dispensary Approval

    Yesterday, Cresco Labs (CRLBF) (CL) announced it had received licenses for its five Illinois medical cannabis dispensaries to sell adult-use cannabis.

  • Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
    Zacks

    Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

    Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.

  • Factors Likely to Decide AB InBev's (BUD) Fate in Q3 Earnings
    Zacks

    Factors Likely to Decide AB InBev's (BUD) Fate in Q3 Earnings

    AB InBev's (BUD) third-quarter sales are likely to reflect gains from improving trends in key markets and premiumization efforts. But currency woes and commodity cost inflation might hurt margins.

  • Philip Morris: Earnings Beat, Sales Lag in Q3
    Market Realist

    Philip Morris: Earnings Beat, Sales Lag in Q3

    Philip Morris reported mixed third-quarter results before the markets opened. The company posted revenues of $7.64 billion—up 1.8% YoY.

  • Aurora Cannabis: Preview of Its Cannabis 2.0 Strategy
    Market Realist

    Aurora Cannabis: Preview of Its Cannabis 2.0 Strategy

    On Wednesday, Aurora Cannabis gave a preview of its Cannabis 2.0 strategy. The company provided plans for the roll-out of edibles, concentrates, and vapes.

  • Investing.com

    NewsBreak: Juul is Halting Online Sales of Some E-Cigarettes

    Investing.com – E-cigarette company Juul Labs will no longer sell sweet and fruity e-cigarette refill pods online, news reports said Thursday.

  • Top Ranked Income Stocks to Buy for October 17th
    Zacks

    Top Ranked Income Stocks to Buy for October 17th

    Top Ranked Income Stocks to Buy for October 17th

  • Implied Volatility Surging for Aurora Cannabis (ACB) Stock Options
    Zacks

    Implied Volatility Surging for Aurora Cannabis (ACB) Stock Options

    Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.

  • Aphria: Analysts’ Target Price and Ratings after Earnings
    Market Realist

    Aphria: Analysts’ Target Price and Ratings after Earnings

    Aphria (APHA) reported impressive results for the first quarter of fiscal 2020 on Tuesday. The stock has gained 9.6% since its earnings.

  • Cannabis Roundup: HEXO, APHA, CRLBF, and CRON
    Market Realist

    Cannabis Roundup: HEXO, APHA, CRLBF, and CRON

    Hexo launched Original Stash, a value cannabis brand. Hexo's CEO stated that the company intends to educate consumers and "disrupt the illicit market."

  • Aurora Cannabis Stock Is Gearing Up for a Breakout
    Market Realist

    Aurora Cannabis Stock Is Gearing Up for a Breakout

    On October 15, Aurora Cannabis closed at $3.76, up 7.12% from the previous session. This performance lagged the S&P; 500’s 1.00% rise on the day.

  • Canopy Growth Acquires Beckley Canopy Therapeutics
    Market Realist

    Canopy Growth Acquires Beckley Canopy Therapeutics

    On October 15, Canopy Growth (CGC) completed the acquisition of cannabinoid-based research company Beckley Canopy Therapeutics.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more